Regadenoson Injection, Solution
Product Images NDC 68083-175

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Regadenoson (NDC 68083-175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Regadenoson-spl-carton (Regadenoson Spl Carton)

Regadenoson Injection is a Pharmacologic Stress Agent used for diagnostic purposes only and must be administered only by intravenous use. Each mL of Regadenoson Injection contains 0.08 mg regadenoson, 10.9 mg of dibasic sodium phosphate dihydrate, 5.4 mg monobasic sodium phosphate monohydrate, 150 mg propylene glycol, 1 mg edetate disodium dihydrate and Water for Injection, g.s.. The dosage must be followed as per the package insert, and the solution must be stored at 20° to 25°C (68° to 77°F). The product is manufactured by Gland Pharma Limited in Hyderabad, India. Batch number is not mentioned.*

FDA Label Image

Regadenoson-spl-structure (Regadenoson Spl Structure)

FDA Label Image

Regadenoson-spl-vial (Regadenoson Spl Vial)

Regadenoson Injection is a pharmacologic stress agent used for diagnostic purposes. It comes in a 5 mL single-dose vial with a concentration of 0.4 mg/5 mL (0.08 mg/mL) and is for intravenous use only. The details on the packaging include a National Drug Code (NDC) of 68083-175-01. The other text is not readable due to being gibberish or containing non-English characters.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.